Ensysce Biosciences Inc (ENSC) - Net Assets
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has net assets worth $-1.11 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.96 Million) and total liabilities ($4.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ENSC PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.11 Million |
| % of Total Assets | -37.56% |
| Annual Growth Rate | -40.95% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 42.44 |
Ensysce Biosciences Inc - Net Assets Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Ensysce Biosciences Inc (ENSC) total market value.
Annual Net Assets for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual net assets of Ensysce Biosciences Inc from 2017 to 2025. Also explore net asset growth rate of Ensysce Biosciences Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.88 Million | -14.65% |
| 2024-12-31 | $3.38 Million | +618.98% |
| 2023-12-31 | $-651.27K | +83.84% |
| 2022-12-31 | $-4.03 Million | +50.61% |
| 2021-12-31 | $-8.16 Million | -22.52% |
| 2020-12-31 | $-6.66 Million | -103.58% |
| 2019-12-31 | $186.17 Million | -5.68% |
| 2018-12-31 | $197.39 Million | +1.09% |
| 2017-12-31 | $195.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ensysce Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13968880600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $459.00 | 0.01% |
| Other Components | $142.93 Million | 4447.60% |
| Total Equity | $3.21 Million | 100.00% |
Ensysce Biosciences Inc Competitors by Market Cap
The table below lists competitors of Ensysce Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Micronet Ltd
TA:MCRNT
|
$9.37 Million |
|
Seacera Group Bhd
KLSE:7073
|
$9.37 Million |
|
Polar Capital Holdings plc
LSE:POLR
|
$9.37 Million |
|
Daekyo Co Ltd
KO:019685
|
$9.37 Million |
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
$9.35 Million |
|
Gold Mountain Ltd
AU:GMN
|
$9.35 Million |
|
Ceres Power Holdings PLC
LSE:CWR
|
$9.34 Million |
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
$9.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ensysce Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,708,422 to 3,213,720, a change of -494,702 (-13.3%).
- Net loss of 10,175,700 reduced equity.
- Share repurchases of 9,847,090 reduced equity.
- New share issuances of 5,075,007 increased equity.
- Other factors increased equity by 14,453,081.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.18 Million | -316.63% |
| Share Repurchases | $9.85 Million | -306.41% |
| Share Issuances | $5.08 Million | +157.92% |
| Other Changes | $14.45 Million | +449.73% |
| Total Change | $- | -13.34% |
Book Value vs Market Value Analysis
This analysis compares Ensysce Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.01x to 3.83x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $32.63 | $0.48 | x |
| 2018-12-31 | $32.87 | $0.48 | x |
| 2019-12-31 | $1894.68 | $0.48 | x |
| 2020-12-31 | $-96.81 | $0.48 | x |
| 2021-12-31 | $-97.10 | $0.48 | x |
| 2022-12-31 | $-22.40 | $0.48 | x |
| 2023-12-31 | $-0.14 | $0.48 | x |
| 2024-12-31 | $2.12 | $0.48 | x |
| 2025-12-31 | $0.13 | $0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ensysce Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -316.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -200.84%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 2.32x
- Recent ROE (-316.63%) is below the historical average (-58.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -0.02% | 0.00% | 0.00x | 1.04x | $-19.56 Million |
| 2018 | 1.08% | 0.00% | 0.00x | 1.04x | $-17.62 Million |
| 2019 | 0.79% | 83.70% | 0.01x | 1.06x | $-17.14 Million |
| 2020 | 0.00% | 1.44% | 11.17x | 0.00x | $722.61K |
| 2021 | 0.00% | -825.38% | 0.22x | 0.00x | $-28.33 Million |
| 2022 | 0.00% | -989.21% | 0.43x | 0.00x | $-24.56 Million |
| 2023 | 0.00% | -475.71% | 0.82x | 0.00x | $-10.58 Million |
| 2024 | -215.37% | -153.30% | 0.93x | 1.51x | $-8.36 Million |
| 2025 | -316.63% | -200.84% | 0.68x | 2.32x | $-10.50 Million |
Industry Comparison
This section compares Ensysce Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ensysce Biosciences Inc (ENSC) | $-1.11 Million | -0.02% | N/A | $9.36 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more